Literature DB >> 32078805

CRISPR-Cas9 Disruption of Aquaporin 1: An Alternative to Glaucoma Eye Drop Therapy?

András M Komáromy1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32078805      PMCID: PMC7054811          DOI: 10.1016/j.ymthe.2020.02.011

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  13 in total

1.  Cost-Utility Analysis of Glaucoma Medication Adherence.

Authors:  Paula Anne Newman-Casey; Mariam Salman; Paul P Lee; Justin D Gatwood
Journal:  Ophthalmology       Date:  2019-10-10       Impact factor: 12.079

2.  Cell turnover in ciliary epithelium compared to other slow renewing epithelia in the adult mouse.

Authors:  T F McDonald; K Green
Journal:  Curr Eye Res       Date:  1988-03       Impact factor: 2.424

3.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

Review 4.  Glaucoma - Next Generation Therapeutics: Impossible to Possible.

Authors:  Christopher M Adams; Rebecca Stacy; Nalini Rangaswamy; Chad Bigelow; Cynthia L Grosskreutz; Ganesh Prasanna
Journal:  Pharm Res       Date:  2018-12-13       Impact factor: 4.200

5.  Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid.

Authors:  Adrian M Timmers; Judith A Newmark; Heikki T Turunen; Tanaz Farivar; Jilin Liu; Chunjuan Song; Guo-Jie Ye; Steven Pennock; Chantelle Gaskin; David R Knop; Mark S Shearman
Journal:  Hum Gene Ther       Date:  2019-10-31       Impact factor: 5.695

Review 6.  Primary open-angle glaucoma.

Authors:  Robert N Weinreb; Christopher K S Leung; Jonathan G Crowston; Felipe A Medeiros; David S Friedman; Janey L Wiggs; Keith R Martin
Journal:  Nat Rev Dis Primers       Date:  2016-09-22       Impact factor: 52.329

7.  The number of people with glaucoma worldwide in 2010 and 2020.

Authors:  H A Quigley; A T Broman
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

Review 8.  The pathophysiology and treatment of glaucoma: a review.

Authors:  Robert N Weinreb; Tin Aung; Felipe A Medeiros
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

9.  Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9.

Authors:  Jiahui Wu; Oliver H Bell; David A Copland; Alison Young; John R Pooley; Ryea Maswood; Rachel S Evans; Peng Tee Khaw; Robin R Ali; Andrew D Dick; Colin J Chu
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

Review 10.  Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives.

Authors:  Alexandra V Garafalo; Artur V Cideciyan; Elise Héon; Rebecca Sheplock; Alexander Pearson; Caberry WeiYang Yu; Alexander Sumaroka; Gustavo D Aguirre; Samuel G Jacobson
Journal:  Prog Retin Eye Res       Date:  2019-12-30       Impact factor: 21.198

View more
  2 in total

1.  Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing.

Authors:  Natalia Rivera-Torres; Kelly Banas; Eric B Kmiec
Journal:  Leuk Lymphoma       Date:  2020-08-20

2.  Long-Term Decrease of Intraocular Pressure in Rats by Viral Delivery of miR-146a.

Authors:  Coralia Luna; Megan Parker; Pratap Challa; Pedro Gonzalez
Journal:  Transl Vis Sci Technol       Date:  2021-07-01       Impact factor: 3.283

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.